Press Release February 25, 2022Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. 0 0 Share
Press Release February 25, 2022Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1. 0 0 Share
Company Ticker News February 25, 2022Here's Why Bristol Myers Squibb Stock Is A Better Pick Over This Pharmaceutical Bellwether 0 0 Share
Company Ticker News February 19, 2022Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review 0 0 Share
Company Ticker News February 18, 2022Bristol Myers Squibb Is My Choice For A Dividend Growth Portfolio 0 0 Share
Company Ticker News February 18, 2022Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative Colitis 0 0 Share
Press Release February 16, 2022Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes 0 0 Share
Press Release February 15, 2022Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion 0 0 Share
Company Ticker News February 15, 2022Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial 0 0 Share
Press Release February 15, 2022Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 0 0 Share
